Ophthalmology venture grabs investors’ attention, raises $330 million
Ollin Biosciences secures $330 million to challenge Roche's Vabsymo in retina disease treatment
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Ollin Biosciences has raised $330 million in Series B financing. The funds will support global Phase 3 development of OLN324, a treatment for diabetic macular edema (DME) and wet age-related macular degeneration (AMD).
Coverage emphasizes the competitive landscape in ophthalmology, particularly the challenge to Roche's Vabsymo. Reports from FirstWord PHARMA, Fierce Biotech, Business Wire, Endpoints News, and statnews.com highlight Ollin's ambitious plans and the significant investment it has attracted.
Ollin's Phase 3 trials for OLN324 are set to commence in the second half of 2026. Coverage does not yet specify the trial locations or the timeline for results.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 9h ago.
Quick answers
What is Ollin Biosciences developing?
Ollin Biosciences is developing OLN324, a treatment for diabetic macular edema (DME) and wet age-related macular degeneration (AMD).
How much funding has Ollin Biosciences raised?
Ollin Biosciences has raised $330 million in Series B financing.
What is the purpose of the funding?
The funding will support the global Phase 3 development of OLN324, with trials commencing in the second half of 2026.
Coverage (5)
- Ollin raises $330M to dethrone Roche's Vabsymo in retina diseases FirstWord PHARMA · 23h ago
- Ollin hauls in $330M to enlist Vabysmo challenger in phase 3 eye disease gauntlet Fierce Biotech · 23h ago
- Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026 Business Wire · 23h ago
- Ollin nets $330M to run Phase 3 trials of Vabysmo challenger from China Endpoints News · 23h ago
- Ophthalmology venture grabs investors’ attention, raises $330 million statnews.com · 23h ago
Topics
Related trends
A Signal of Future Alzheimer's May Be Hidden in Your Eyes
Researchers are exploring whether retinal images and AI can predict Alzheimer's risk years before symptoms appear